Imbed Biosciences

Imbed Biosciences is an innovator in advanced wound care, leveraging its proprietary SAM™ platform to create ultra-thin, fully synthetic, and antimicrobial hydrogel matrices. The company has a commercial portfolio including Surgaflex™, Pelashield™, and Microlyte® brands, recently enhanced with the launch of SAM™ PainGuard™, which integrates lidocaine for dual-action pain and infection management. As a private, revenue-generating medical device manufacturer with FDA registration and ISO 13485 certification, Imbed targets a significant global wound care market with its differentiated, synthetic alternatives to biological grafts.

SAM™ (Synthetic Antimicrobial Matrix): A proprietary, ultra-thin, fully synthetic, and biocompatible hydrogel matrix composed of bioresorbable polymers. It integrates active agents (e.g., antimicrobial silver, lidocaine), conforms to the wound bed, maintains a moist healing environment, and is bioresorbed within ~1 week without requiring removal.

Imbed competes in the advanced wound dressing and skin substitute market against major players like 3M, Smith & Nephew, Mölnlycke, and Integra LifeSciences, as well as other biological graft manufacturers. Its key competitive differentiation is its fully synthetic, antimicrobial, and drug-integratable SAM™ matrix, which avoids the risks and variability associated with animal- or human-derived products.